Literature DB >> 925705

Myocardial creatine kinase isoenzyme in serum after subarachnoid haemorrhage.

G Fabinyi, D Hunt, L McKinley.   

Abstract

The myocardial isoenzyme of creatine kinase (MB CK) has been demonstrated in the serum of seven of 16 patients presenting with acute subarachnoid haemorrhage. All patients with elevated MB CK levels exhibited at some stage either intracranial arterial spasm as demonstrated by cerebral angiography, or a focal reversible neurological deficit not due to direct pressure by either intracranial haematoma or aneurysm. The presence of MB CK isoenzymes in sera of patients with subarachnoid haemorrhage may be an index of cerebral ischaemia, and may thus be of value in determining optimal timing of surgery or, ultimately, the long-term prognosis. Changes in the sympathetic nervous system may be a common factor producing both MB isoenzyme release from the myocardium and intracranial arterial spasm.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 925705      PMCID: PMC492842          DOI: 10.1136/jnnp.40.8.818

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  A spectrophotometric method for the determination of creatine phosphokinase and myokinase.

Authors:  I T OLIVER
Journal:  Biochem J       Date:  1955-09       Impact factor: 3.857

2.  Creatine kinase MB isoenzyme studies in diagnosis of myocardial infarction.

Authors:  A F Smith; D Radford; C P Wong; M F Oliver
Journal:  Br Heart J       Date:  1976-03

Review 3.  Myocardial damage and cardiac arrhythmias after intracranial hemorrhage. A critical review.

Authors:  D J Weidler
Journal:  Stroke       Date:  1974 Nov-Dec       Impact factor: 7.914

4.  Serum-creatine-kinase in cases of stroke, head injury, and meningitis.

Authors:  H Dubo; D C Park; R J Pennington; R M Kalbag; J N Walton
Journal:  Lancet       Date:  1967-10-07       Impact factor: 79.321

5.  Serum creatine phosphokinase isoenzyme (CPK2) in myositis. A report of six cases.

Authors:  K Brownlow; F R Elevitch
Journal:  JAMA       Date:  1974-11-25       Impact factor: 56.272

6.  Serum creatine phosphokinase (CPK ) isoenzymes after intramuscular injections, surgery, and myocardial infarction. Experimental and clinical studies.

Authors:  M S Klein; W E Shell; B E Sobel
Journal:  Cardiovasc Res       Date:  1973-05       Impact factor: 10.787

7.  A serum isozyme study in muscular dystrophy. Particular reference to creatine kinase, aspartate aminotransferase, and lactic acid dehydrogenase isozymes.

Authors:  H Somer; M Donner; J Murros; A Konttinen
Journal:  Arch Neurol       Date:  1973-11

8.  The importance of identification of the myocardial-specific isoenzyme of creatine phosphokinase (MB form) in the diagnosis of acute myocardial infarction.

Authors:  G S Wagner; C R Roe; L E Limbird; R A Rosati; A G Wallace
Journal:  Circulation       Date:  1973-02       Impact factor: 29.690

9.  Electrocardiographic and serum enzyme change in subarachnoid hemorrhage.

Authors:  D Hunt; C McRae; P Zapf
Journal:  Am Heart J       Date:  1969-04       Impact factor: 4.749

10.  Management of ischemic complications after subarachnoid hemorrhage.

Authors:  T M Sundt
Journal:  J Neurosurg       Date:  1975-10       Impact factor: 5.115

View more
  10 in total

1.  Predictors of left ventricular regional wall motion abnormalities after subarachnoid hemorrhage.

Authors:  Avinash Kothavale; Nader M Banki; Alexander Kopelnik; Sirisha Yarlagadda; Michael T Lawton; Nerissa Ko; Wade S Smith; Barbara Drew; Elyse Foster; Jonathan G Zaroff
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

2.  Adrenoceptor polymorphisms and the risk of cardiac injury and dysfunction after subarachnoid hemorrhage.

Authors:  Jonathan G Zaroff; Ludmila Pawlikowska; Jacob C Miss; Sirisha Yarlagadda; Connie Ha; Achal Achrol; Pui-Yan Kwok; Charles E McCulloch; Michael T Lawton; Nerissa Ko; Wade Smith; William L Young
Journal:  Stroke       Date:  2006-05-25       Impact factor: 7.914

3.  Prevalence and implications of diastolic dysfunction after subarachnoid hemorrhage.

Authors:  Alexander Kopelnik; Landis Fisher; Jacob C Miss; Nader Banki; Poyee Tung; Michael T Lawton; Nerissa Ko; Wade S Smith; Barbara Drew; Elyse Foster; Jonathan Zaroff
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Chick embryo partial ischemia model: a new approach to study ischemia ex vivo.

Authors:  Syamantak Majumder; M Ilayaraja; Himabindu Reddy Seerapu; Swaraj Sinha; Jamila H Siamwala; Suvro Chatterjee
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

5.  Electrocardiographic changes during and after isoflurane-induced hypotension for neurovascular surgery.

Authors:  P H Manninen; A M Lam; A W Gelb
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

6.  Neurogenic Cardiac Injury.

Authors:  Nader M. Banki; Jonathan G. Zaroff
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-12

7.  Electrocardiographic alterations in subarachnoid haemorrhage. Correlation between spasm of the arteries of the left side on the brain and T inversion and QT prolongation.

Authors:  T Stober; K Kunze
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

8.  Cortisol dynamics are associated with electrocardiographic abnormalities following the aneurysmal subarachnoid hemorrhage.

Authors:  Julius July; Suryani As'ad; F X Budhianto Suhadi; Andi A Islam
Journal:  J Cardiovasc Dis Res       Date:  2012-10

9.  Ischemia modified albumin increase indicating cardiac damage after experimental subarachnoid hemorrhage.

Authors:  Şerefden Açıkgöz; Nurullah Edebali; Figen Barut; Murat Can; İshak Özel Tekin; Çağatay Büyükuysal; Bektaş Açıkgöz
Journal:  BMC Neurosci       Date:  2014-02-24       Impact factor: 3.288

10.  Cardiac parameters affect prognosis in patients with non-large atherosclerotic infarction.

Authors:  Ya-Ying Zeng; Wen-Bo Zhang; Lin Cheng; Li Wang; Dan-Dan Geng; Wen-Jie Tang; Jin-Cai He; Bin-Bin Deng
Journal:  Mol Med       Date:  2021-01-06       Impact factor: 6.354

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.